Online inquiry

IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15905MR)

This product GTTS-WQ15905MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15905MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2813MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ3558MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ11856MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ12581MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ11095MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ970MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ4915MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ4628MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW